Perturbation of dopaminergic transmission is implicated as a risk factor of HIV-1 associated neurocognitive disorders (HAND). Dopaminergic system plays a causal role in drug rewarding and modulation of the brain function including cognition. Prefrontal cortex is an important brain region for higher cognitive function, where norepinephrine transporter (NET) is the primary mechanism of homeostatic regulation of stable synaptic dopaminergic tone. HIV-1 Tat protein and cocaine synergistically increase synaptic dopamine levels, thereby producing neurocognitive impairment. Our initial findings show that in vitro exposure to recombinant Tat1-86 inhibits dopamine and norepinephrine reuptake by dopamine transporter (DAT) and NET and Tat binds to DAT and NET through a direct protein-protein interaction. We have demonstrated that Tat-induced inhibition of DAT function is mediated by binding to allosteric binding site(s) on DAT, not by interacting with the DA uptake site. Accordingly, attenuating Tat binding to DAT would be expected to have minimal influence on physiological DA transport. Indeed, our recent findings show that a novel quinazoline series of allosteric modulators decrease cocaine potency for inhibition of DA uptake and attenuate Tat-induced inhibition of DA reuptake and cocaine binding by DAT. We hypothesize that Tat, via the unique allosteric modulatory sites, perturbs the DAT and NET regulatory network that normally sustains concentrative DA or NE transport and potentiates cocaine?s effect on DAT and NET, resulting in DA/NE-linked neuropsychiatric dysfunction prominently featured in HAND. We will (Aim 1) Identify the binding sites for Tat in human NET, and explore allosteric modulation of this transporter by Tat and cocaine;
(Aim 2) determine the pathogenic role of DAT/NET-mediated dopaminergic transmission in inducible Tat transgenic mice by assessment of Fast-scan cyclic voltammetry and whole cell patch clamp recording;
and (Aim 3) perform proof of concept studies using novel allosteric modulators to establish their potential for therapeutic application in HAND using integrated computational modeling, pharmacological, and behavioral approaches. Our long-term goal is to explore new ways to target DAT/NET for therapeutic interventions to improve neurocognitive dysfunction of HAND in concurrent cocaine abusers.

Public Health Relevance

Despite the widespread use of efficacious antiretroviral therapies in controlling peripheral infection and improving life of HIV patients, the prevalence and severity of HIV-1-associated neurocognitive disorders (HAND) are greatly enhanced (~70%) due to concomitant use of drugs of abuse such as cocaine. Dysregulation of dopamine signaling has been implicated as a risk determinant of HAND. Our study will novel, previously uncertain molecular mechanism(s) driving Tat-induced dysfunction of DA system by direct interaction with monoamine transporters, which is associated with Tat-mediated cognitive/behavioral deficits.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA035714-07
Application #
9649184
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Tsai, Shang-Yi Anne
Project Start
2013-07-01
Project End
2023-01-31
Budget Start
2019-02-01
Budget End
2020-01-31
Support Year
7
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of South Carolina at Columbia
Department
Type
Schools of Pharmacy
DUNS #
041387846
City
Columbia
State
SC
Country
United States
Zip Code
29208
Zhu, Jun; Ananthan, Subramaniam; Zhan, Chang-Guo (2017) The role of human dopamine transporter in NeuroAIDS. Pharmacol Ther :
Sun, Wei-Lun; Quizon, Pamela M; Yuan, Yaxia et al. (2017) Allosteric modulatory effects of SRI-20041 and SRI-30827 on cocaine and HIV-1 Tat protein binding to human dopamine transporter. Sci Rep 7:3694
Sun, Wei-Lun; Quizon, Pamela M; Zhu, Jun (2016) Molecular Mechanism: ERK Signaling, Drug Addiction, and Behavioral Effects. Prog Mol Biol Transl Sci 137:1-40
Zhu, Jun; Yuan, Yaxia; Midde, Narasimha M et al. (2016) HIV-1 transgenic rats display an increase in [(3)H]dopamine uptake in the prefrontal cortex and striatum. J Neurovirol 22:282-92
Yuan, Yaxia; Quizon, Pamela M; Sun, Wei-Lun et al. (2016) Role of Histidine 547 of Human Dopamine Transporter in Molecular Interaction with HIV-1 Tat and Dopamine Uptake. Sci Rep 6:27314
Yuan, Yaxia; Huang, Xiaoqin; Zhu, Jun et al. (2016) Computational modeling of human dopamine transporter structures, mechanism and its interaction with HIV-1 transactivator of transcription. Future Med Chem :
Gao, Jie; Midde, Narasimha; Zhu, Jun et al. (2016) Synthesis and biological evaluation of ranitidine analogs as multiple-target-directed cognitive enhancers for the treatment of Alzheimer's disease. Bioorg Med Chem Lett 26:5573-5579
Quizon, Pamela M; Sun, Wei-Lun; Yuan, Yaxia et al. (2016) Molecular mechanism: the human dopamine transporter histidine 547 regulates basal and HIV-1 Tat protein-inhibited dopamine transport. Sci Rep 6:39048
Bucci, Mirella (2015) Viral mechanisms: Tat modulates DAT. Nat Chem Biol 11:240
Yuan, Yaxia; Huang, Xiaoqin; Midde, Narasimha M et al. (2015) Molecular mechanism of HIV-1 Tat interacting with human dopamine transporter. ACS Chem Neurosci 6:658-665

Showing the most recent 10 out of 18 publications